Hims & Hers Health, Inc.: Jim Cramer Warns ‘The Gravy Train Might Be Over’ After FDA’s Ozempic Update
We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...
Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor
With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...
The GLP-1 Revolution — Everyone And Their Moms Are On GLP-1s
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
UK stock investors are piling into this under-the-radar share up 270%! Should I join them?
This writer noticed that UK stock investors have been buying an obscure share that fell 26% yesterday but is still up nearly ...
What is metformin, the old diabetes drug some people are taking for weight loss?
The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable semaglutide, the active ingredient in weight loss juggernauts Wegovy and ...
Eli Lilly cuts price of weight-loss drug Zepbound as competition heats up
Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...
Novo Nordisk (0QIU) Receives a Buy from J.P. Morgan
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...